Shares shifted as Eli Lilly secured FDA approval on April 1 for its once-daily weight-loss pill, the first oral obesity drug patients can take at any time without food or water restrictions. Lilly, which has already stockpiled $1.5 billion worth of inventory, plans to launch the product quickly , with shipping beginning April 6 via its direct-to-consumer platform, followed by broad retail pharmacy availability . The stock rose roughly 4% on announcement day, but has since flattened near $935 — raising a pointed question: has the good news already been priced in?
A Record-Fast Approval, But the Real Test Starts Now
The FDA cleared the drug just 50 days after filing — the fastest approval of a new molecular entity since 2002 , made possible by an expedited federal review program. Speed to market matters: Novo Nordisk's rival pill, approved in December, has already seen rapid adoption, which may dent Lilly's uptake . Weekly new-prescription data will be the key scoreboard to watch.
Wall Street Is Betting Big — With a Wide Range of Estimates
Analysts forecast 2026 revenues between $1.5 billion (Guggenheim) and $2.8 billion (Citi), with long-term peak sales potentially surpassing $40 billion . J.P. Morgan anticipates $6 billion by 2027 . That enormous spread reflects genuine uncertainty: Bernstein warns that free sampling programs, gradual dose increases, and pricing pressure could suppress early revenue despite strong prescription growth .
A Price War Is Already Underway
Lilly originally planned to charge up to $399/month out-of-pocket, but after Novo undercut it at $299, Lilly matched that ceiling price . Insured patients may pay as little as $25/month . Lower prices expand the addressable patient pool — CEO David Ricks notes fewer than 1 in 10 eligible patients currently take a GLP-1 drug — but they also compress profit margins on every pill sold.
The Convenience Edge Is Real, But Efficacy Trails Injectables
Novo's pill showed 13.6% weight loss versus 11.2% for Lilly's drug in respective trials . However, as a small molecule, Lilly's pill is easier and cheaper to manufacture than Novo's peptide-based competitor , and its no-restrictions dosing removes an adherence barrier that has plagued oral rivals. The consensus analyst price target sits at $1,222 , implying roughly 30% upside — but only if Lilly can convert convenience into market share faster than Novo can defend its head start.